Ticagrelor Protects the Heart Against Reperfusion Injury and Improves Remodeling After Myocardial Infarction | Zendy

Yumei Ye | Zendy; Gilad D. Birnbaum | Zendy; J. R. PerezPolo | Zendy; Manjyot K. Nanhwan | Zendy; Sven Nylander | Zendy; Yochai Birnbaum | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ticagrelor Protects the Heart Against Reperfusion Injury and Improves Remodeling After Myocardial Infarction

Author(s) -

Yumei Ye,

Gilad D. Birnbaum,

J. R. PerezPolo,

Manjyot K. Nanhwan,

Sven Nylander,

Yochai Birnbaum

Publication year - 2015

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.115.305655

Subject(s) - ticagrelor , clopidogrel , medicine , p2y12 , ejection fraction , myocardial infarction , cardiology , intraperitoneal injection , adenosine , anesthesia , pharmacology , heart failure

In addition to P2Y12 receptor antagonism, ticagrelor inhibits adenosine cell uptake. Prior data show that 7-day pretreatment with ticagrelor limits infarct size. We explored the acute effects of ticagrelor and clopidogrel on infarct size and potential long-term effects on heart function.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research